BIODESIX, INC. |
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
| 1.28 USD | -0.78% |
|
+2.40% | -30.43% |
| Apr. 09 | Biodesix, Inc. announced that it has received $34.999422 million in funding | CI |
| Apr. 05 | Top Midday Decliners | MT |
Financials (USD)
| Sales 2024 * | 65.25M | Sales 2025 * | 79.05M | Capitalization | 145M |
|---|---|---|---|---|---|
| Net income 2024 * | -39M | Net income 2025 * | -32M | EV / Sales 2024 * | 2.23 x |
| Net cash position 2024 * | - | Net cash position 2025 * | - | EV / Sales 2025 * | 1.84 x |
| P/E ratio 2024 * |
-3.2
x | P/E ratio 2025 * |
-4.2
x | Employees | 217 |
| Yield 2024 * |
-
| Yield 2025 * |
-
| Free-Float | 37.56% |
More Fundamentals
* Assessed data
More news
Latest transcript on Biodesix, Inc.
More recommendations
More press releases
| 1 day | -0.78% | ||
| 1 week | +2.40% | ||
| Current month | -10.49% | ||
| 1 month | -7.25% | ||
| 3 months | -35.35% | ||
| 6 months | -20.00% | ||
| Current year | -30.43% |
1 week
1.20
1.30
1 month
1.151.55
Current year
1.152.21
1 year
1.032.21
3 years
0.9617.91
5 years
0.9631.99
10 years
0.9631.99
| Managers | Title | Age | Since |
|---|---|---|---|
Scott Hutton
CEO | Chief Executive Officer | 52 | - |
Robin Cowie
DFI | Director of Finance/CFO | 44 | 11-02-28 |
James R. Jett
CTO | Chief Tech/Sci/R&D Officer | - | 15-12-31 |
| Members of the board | Title | Age | Since |
|---|---|---|---|
John Patience
CHM | Chairman | 76 | 08-05-31 |
Jack Schuler
BRD | Director/Board Member | 83 | 11-12-31 |
Jon Kayyem
BRD | Director/Board Member | 60 | 21-12-05 |
| Date | Price | Change | Volume |
|---|---|---|---|
| 24-04-23 | 1.28 | -0.78% | 36,906 |
| 24-04-22 | 1.29 | +3.20% | 48,595 |
| 24-04-19 | 1.25 | 0.00% | 47,678 |
| 24-04-18 | 1.25 | +3.31% | 45,441 |
| 24-04-17 | 1.21 | -3.20% | 38,236 |
Delayed Quote Nasdaq, April 23, 2024 at 04:00 pm EDT
More quotes
Biodesix, Inc. (Biodesix) is a diagnostic solutions and services company. The Company develops diagnostic tests addressing clinical questions by combining multi-omics through the power of artificial intelligence. Biodesix offers over five Medicare-covered tests for patients with lung diseases. The blood based Nodify Lung Nodule Risk Assessment testing strategy, consisting of the Nodify XL2 and the Nodify CDT tests, evaluates the risk of malignancy in incidental pulmonary nodules, enabling physicians to better triage patients to the appropriate course of action. The blood based IQLung strategy for lung cancer patients integrates the GeneStrat targeted ddPCR test, the GeneStrat NGS test and the VeriStrat test to support treatment decisions across all stages of lung cancer. Biodesix also leverages the advanced Diagnostic Cortex artificial intelligence (AI) platform, to collaborate with biotechnology and pharmaceutical companies to solve complex diagnostic challenges in lung disease.
Calendar
2024-05-07
- Q1 2024 Earnings Release (Projected)
Trading Rating
Investor Rating
ESG Refinitiv
C+
Sell
Buy
Mean consensus
BUY
Number of Analysts
2
Last Close Price
1.28
USD
Average target price
3.5
USD
Spread / Average Target
+173.44%
EPS Revisions
| 1st Jan change | Capi. | |
|---|---|---|
| -30.43% | 145M | |
| -16.65% | 8.36B | |
| +40.44% | 3.6B | |
| -29.20% | 2.87B | |
| -7.88% | 2.47B | |
| -10.60% | 2.24B | |
| -18.40% | 1.56B | |
| -39.52% | 1.23B | |
| +9.05% | 1.13B | |
| -16.87% | 1.04B |
- Stock Market
- Equities
- BDSX Stock
